Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00540)
Name
Pomalidomide
Synonyms    Click to Show/Hide the Synonyms of This API
Pomalidomide; 19171-19-8; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; Actimid; CC-4047; Pomalyst; Imnovid; 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; 4-Aminothalidomide; Pomalidomide (CC-4047); 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide; CC 4047; 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-; IMiD 3; IMID-3; CHEBI:72690; MFCD12756407; 4-amino-2-(2,6-dioxo-3-piperidinyl)-1H-Isoindole-1,3(2H)-dione; 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; Pomalidomide [USAN:INN]; HSDB 8222; Pomalyst (TN); 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; PubChem22200; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide; 3-Aminophthalimidoglutarimide; cc-449; MLS006011261; CHEMBL43452; SCHEMBL369172; GTPL7348; Pomalidomide (JAN/USAN/INN); SCHEMBL19250920; BDBM65456; IMID-4047; CDC-394; DTXSID40893458; Pomalidomide, >=98% (HPLC); HMS3655G05; HMS3744K07; Actimid; CC 4047; BCP02890; BCP09107; EBD24712; ANW-69609; NSC767909; NSC775351; AKOS013400288; ACN-034796; CCG-264684; CS-0165; DB08910; LS40023; NSC-767909; NSC-775351; SB16552; NCGC00346551-01; NCGC00346551-03; AC-26970; AK104087; AS-17905; BP-24477; DA-21486; HY-10984; SMR004703012; SY054807; BCP0726000263; AB0021203; FT-0697903; SW218099-2; D08976; W-5536; AB01565777_02; 171P198; SR-01000941573; J-012392; J-514302; Phthalimide, 3-amino-N-(2,6-dioxo-3-piperidyl)-; Q7227206; SR-01000941573-1; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 4-amino-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidinyl)isoindole-1,3-dione; 4-Amino-2-(2,6-dioxo-3-piperidyl) isoindoline -1,3-dione; Lipopolysaccharides from Escherichia coli 055:B5 pound>>Lipopolysaccharides pound>> lipoglycans pound>>endotoxins
Clinical Status
Approved
Disease Indication Breast cancer ICD-11: 2C60 [1]
PubChem CID
134780
Formula
C13H11N3O4
Canonical SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
InChI
1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
InChIKey
UVSMNLNDYGZFPF-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=134780"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 273.24 Topological Polar Surface Area 110
XlogP 0.2 Complexity 504
Heavy Atom Count 20 Rotatable Bond Count 1
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Pomalidomide 1 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium stearyl fumarate DIG Info Leukemia K562 cells (IC50 = 20.2 ug.mL-1) [3]
          Pomalidomide 2 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium stearyl fumarate DIG Info Leukemia K562 cells (IC50 = 20.2 ug.mL-1) [3]
          Pomalidomide 3 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium stearyl fumarate DIG Info Leukemia K562 cells (IC50 = 20.2 ug.mL-1) [3]
          Pomalidomide 4 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Starch, corn
                   Dosage Form Oral Capsule
                   Company Celgene Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium stearyl fumarate DIG Info Leukemia K562 cells (IC50 = 20.2 ug.mL-1) [3]
References
1 FDA label for approved pomalidomide from the official website of the U.S. Food and Drug Administration.
2 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
3 Synthesis and evaluation of (-)-Massoialactone and analogues as potential anticancer and anti-inflammatory agents. Eur J Med Chem. 2014 Apr 9; 76:291-300.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.